Chemical: Drug
infliximab

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for infliximab

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA HLA-DRB1 *04:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:02 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:03 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:04 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:05 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:06 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:07 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:08 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *15:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *15:02:01 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1043879 NC_000001.10:g.25570081T>C, NC_000001.11:g.25243590T>C, NM_020317.4:c.716A>G, NP_064713.3:p.Glu239Gly, NR_135143.1:n.2509A>G, NR_135144.1:n.1584A>G, XM_011541797.1:c.716A>G, XM_011541798.1:c.*79A>G, XP_011540099.1:p.Glu239Gly, XR_241196.1:n.2280A>G, XR_241197.1:n.1962A>G, XR_241198.1:n.1689A>G, XR_241199.1:n.1858A>G, XR_241200.1:n.1629A>G, XR_241201.1:n.1038A>G, XR_946709.1:n.2280A>G, XR_946710.1:n.1962A>G, XR_946711.1:n.1689A>G, XR_946712.1:n.1858A>G, XR_946713.1:n.1584A>G, rs17844932, rs17857662, rs17859787, rs57469912
T > -
T > C
SNP
E239G
No VIP available No Clinical Annotations available VA
rs10499194 NC_000006.11:g.138002637C>T, NC_000006.12:g.137681500C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1050501 NC_000001.10:g.161643798T>C, NC_000001.11:g.161674008T>C, NG_023318.1:g.15894T>C, NM_001002273.2:c.692T>C, NM_001002274.2:c.695T>C, NM_001002275.2:c.692T>C, NM_001190828.1:c.674T>C, NM_004001.4:c.695T>C, NP_001002273.1:p.Ile231Thr, NP_001002274.1:p.Ile232Thr, NP_001002275.1:p.Ile231Thr, NP_001177757.1:p.Ile225Thr, NP_003992.3:p.Ile232Thr, XM_011509292.1:c.*486T>C, rs17416926, rs3171037, rs3818924, rs59522454
T > C
SNP
I231T
No VIP available CA VA
rs1059150 NC_000020.10:g.57605439T>G, NC_000020.11:g.59030384T>G, NG_031871.1:g.6984A>C, NM_006886.3:c.78A>C, NP_008817.1:p.Ala26=, NR_037929.1:n.782A>C, NR_037930.1:n.523A>C, rs3199795
T > -
T > G
SNP
A26A
No VIP available CA VA
rs1061622 NC_000001.10:g.12252955T>G, NC_000001.11:g.12192898T>G, NG_029791.1:g.30896T>G, NM_001066.2:c.587T>G, NP_001057.1:p.Met196Arg, XM_011542060.1:c.587T>G, XM_011542061.1:c.587T>G, XM_011542062.1:c.566T>G, XM_011542063.1:c.587T>G, XP_011540362.1:p.Met196Arg, XP_011540363.1:p.Met196Arg, XP_011540364.1:p.Met189Arg, XP_011540365.1:p.Met196Arg, XR_244793.1:n.692T>G, rs13306722, rs1681698, rs17037789, rs17883437, rs2228492, rs52797629, rs60195947
T > G
SNP
M196R
No VIP available No Clinical Annotations available VA
rs10903129 NC_000001.10:g.25768937A>G, NC_000001.11:g.25442446A>G, NM_001282564.1:c.81-4316A>G, NM_018202.5:c.81-4316A>G, XM_005245931.1:c.81-4316A>G, XM_005245932.1:c.81-4316A>G, XM_005245933.1:c.80+11268A>G, XM_011541704.1:c.-531-4316A>G, rs17537348, rs56639081, rs60964820
A > G
SNP
No VIP available CA VA
rs10919563 NC_000001.10:g.198700442G>A, NC_000001.11:g.198731313G>A, NG_007730.1:g.97218G>A, NM_002838.4:c.1865-304G>A, NM_080921.3:c.1382-304G>A, XM_006711472.2:c.1721-304G>A, XM_006711473.2:c.1667-304G>A, XM_006711474.2:c.1523-304G>A, rs61716706
G > A
SNP
No VIP available CA VA
rs1143634 NC_000002.11:g.113590390G>A, NC_000002.12:g.112832813G>A, NG_008851.1:g.8967C>T, NM_000576.2:c.315C>T, NP_000567.1:p.Phe105=, XM_006712496.1:c.81C>T, XP_006712559.1:p.Phe27=, rs11541230, rs17598550, rs3730338, rs386518185, rs57848697
G > A
SNP
F105F
No VIP available No Clinical Annotations available VA
rs11586238 NC_000001.10:g.117263138C>G, NC_000001.11:g.116720516C>G, rs17377407, rs56747362
C > G
SNP
No VIP available CA VA
rs1264457 NC_000006.11:g.30458064G=, NC_000006.11:g.30458064G>A, NC_000006.12:g.30490287G=, NC_000006.12:g.30490287G>A, NM_005516.5:c.382G=, NM_005516.5:c.382G>A, NP_005507.3:p.Gly128=, NP_005507.3:p.Gly128Arg, NT_113891.2:g.1970128A=, NT_113891.2:g.1970128A>G, NT_113891.3:g.1970022A=, NT_113891.3:g.1970022A>G, NT_167245.1:g.1751704A=, NT_167245.1:g.1751704A>G, NT_167245.2:g.1746119A=, NT_167245.2:g.1746119A>G, NT_167246.1:g.1806142G=, NT_167246.1:g.1806142G>A, NT_167246.2:g.1800522G=, NT_167246.2:g.1800522G>A, NT_167247.1:g.1839928G=, NT_167247.1:g.1839928G>A, NT_167247.2:g.1834343G=, NT_167247.2:g.1834343G>A, NT_167248.1:g.1750979A=, NT_167248.1:g.1750979A>G, NT_167248.2:g.1745383A=, NT_167248.2:g.1745383A>G, NT_167249.1:g.1790354A=, NT_167249.1:g.1790354A>G, NT_167249.2:g.1791056A=, NT_167249.2:g.1791056A>G, rs115492845, rs117192178, rs17195355, rs7767992
G > A
SNP
G128R
No VIP available No Clinical Annotations available VA
rs13031237 NC_000002.11:g.61136129G>T, NC_000002.12:g.60908994G>T, NM_001291746.1:c.395-7883G>T, NM_002908.3:c.395-7883G>T, XM_005264470.1:c.395-7883G>T, XM_005264471.1:c.395-7883G>T, XM_005264472.1:c.395-7883G>T, XM_011533010.1:c.101-7883G>T, rs52833967, rs56896973
G > T
SNP
No VIP available CA VA
rs1799724 NC_000006.11:g.31542482C>T, NC_000006.12:g.31574705C>T, NG_007462.1:g.4133C>T, NG_012010.1:g.7607C>T, NM_000594.3:c.-1037C>T, NM_000595.3:c.*1012C>T, NM_001159740.2:c.*1012C>T, NT_113891.2:g.3052098C>T, NT_113891.3:g.3051992C>T, NT_167245.1:g.2828023C>T, NT_167245.2:g.2822438C>T, NT_167246.1:g.2885366C>T, NT_167246.2:g.2879746C>T, NT_167247.1:g.2922188C>T, NT_167247.2:g.2916603C>T, NT_167248.1:g.2836120C>T, NT_167248.2:g.2830524C>T, NT_167249.1:g.2873283C>T, NT_167249.2:g.2873985C>T, XM_011514614.1:c.*1012C>T, XM_011514615.1:c.*1012C>T, XM_011514616.1:c.*1012C>T, XM_011514617.1:c.*1012C>T, XM_011514618.1:c.*1012C>T, XM_011547250.1:c.*1012C>T, XM_011547653.1:c.*1012C>T, XM_011547654.1:c.*1012C>T, XM_011547883.1:c.*1012C>T, XM_011547884.1:c.*1012C>T, XM_011547885.1:c.*1012C>T, XM_011547886.1:c.*1012C>T, XM_011547887.1:c.*1012C>T, XM_011548050.1:c.*1012C>T, XM_011548051.1:c.*1012C>T, XM_011548242.1:c.*1012C>T, XM_011548243.1:c.*1012C>T, XM_011548436.1:c.*1012C>T, XM_011548437.1:c.*1012C>T, XM_011548438.1:c.*1012C>T, XM_011548439.1:c.*1012C>T, XM_011548440.1:c.*1012C>T, XR_952245.1:n.-1983G>A, rs112098114, rs114464955, rs117934520, rs36205301, rs3807038, rs4151108
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1799964 NC_000006.11:g.31542308T=, NC_000006.11:g.31542308T>C, NC_000006.12:g.31574531T=, NC_000006.12:g.31574531T>C, NG_007462.1:g.3959T=, NG_007462.1:g.3959T>C, NG_012010.1:g.7433T=, NG_012010.1:g.7433T>C, NM_000594.3:c.-1211C>T, NM_000594.3:c.-1211T>C, NM_000595.3:c.*838C>T, NM_000595.3:c.*838T>C, NM_001159740.2:c.*838C>T, NM_001159740.2:c.*838T>C, NT_113891.2:g.3051924T=, NT_113891.2:g.3051924T>C, NT_113891.3:g.3051818T=, NT_113891.3:g.3051818T>C, NT_167245.1:g.2827849C=, NT_167245.1:g.2827849C>T, NT_167245.2:g.2822264C=, NT_167245.2:g.2822264C>T, NT_167246.1:g.2885192T=, NT_167246.1:g.2885192T>C, NT_167246.2:g.2879572T=, NT_167246.2:g.2879572T>C, NT_167247.1:g.2922014C=, NT_167247.1:g.2922014C>T, NT_167247.2:g.2916429C=, NT_167247.2:g.2916429C>T, NT_167248.1:g.2835946C=, NT_167248.1:g.2835946C>T, NT_167248.2:g.2830350C=, NT_167248.2:g.2830350C>T, NT_167249.1:g.2873109T=, NT_167249.1:g.2873109T>C, NT_167249.2:g.2873811T=, NT_167249.2:g.2873811T>C, XM_011514614.1:c.*838C>T, XM_011514614.1:c.*838T>C, XM_011514615.1:c.*838C>T, XM_011514615.1:c.*838T>C, XM_011514616.1:c.*838C>T, XM_011514616.1:c.*838T>C, XM_011514617.1:c.*838C>T, XM_011514617.1:c.*838T>C, XM_011514618.1:c.*838C>T, XM_011514618.1:c.*838T>C, XM_011547250.1:c.*838C>T, XM_011547250.1:c.*838T>C, XM_011547653.1:c.*838C>T, XM_011547653.1:c.*838T>C, XM_011547654.1:c.*838C>T, XM_011547654.1:c.*838T>C, XM_011547883.1:c.*838C>T, XM_011547883.1:c.*838T>C, XM_011547884.1:c.*838C>T, XM_011547884.1:c.*838T>C, XM_011547885.1:c.*838C>T, XM_011547885.1:c.*838T>C, XM_011547886.1:c.*838C>T, XM_011547886.1:c.*838T>C, XM_011547887.1:c.*838C>T, XM_011547887.1:c.*838T>C, XM_011548050.1:c.*838C>T, XM_011548050.1:c.*838T>C, XM_011548051.1:c.*838C>T, XM_011548051.1:c.*838T>C, XM_011548242.1:c.*838C>T, XM_011548242.1:c.*838T>C, XM_011548243.1:c.*838C>T, XM_011548243.1:c.*838T>C, XM_011548436.1:c.*838C>T, XM_011548436.1:c.*838T>C, XM_011548437.1:c.*838C>T, XM_011548437.1:c.*838T>C, XM_011548438.1:c.*838C>T, XM_011548438.1:c.*838T>C, XM_011548439.1:c.*838C>T, XM_011548439.1:c.*838T>C, XM_011548440.1:c.*838C>T, XM_011548440.1:c.*838T>C, XR_926695.1:n.-1833A>G, XR_926695.1:n.-1833G>A, XR_952245.1:n.-1809A>G, XR_952245.1:n.-1809G>A, XR_952708.1:n.-1868A>G, XR_952708.1:n.-1868G>A, XR_952889.1:n.-1833A>G, XR_952889.1:n.-1833G>A, XR_952970.1:n.-1868A>G, XR_952970.1:n.-1868G>A, XR_953043.1:n.-1868A>G, XR_953043.1:n.-1868G>A, XR_953113.1:n.-1833A>G, XR_953113.1:n.-1833G>A, rs115160975, rs117348084, rs17207141, rs36205303, rs56648300, rs57009373, rs7755285
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1800471 NC_000019.10:g.41352971C>G, NC_000019.9:g.41858876C>G, NG_013091.1:g.16203G>C, NG_013364.1:g.5956G>C, NM_000660.5:c.74G>C, NP_000651.3:p.Arg25Pro, XM_005259150.1:c.-30+1769C>G, XM_005259187.1:c.74G>C, XM_011527242.1:c.74G>C, XP_005259244.1:p.Arg25Pro, XP_011525544.1:p.Arg25Pro, rs4987231
C > G
SNP
R25P
No VIP available CA VA
rs1800629 NC_000006.11:g.31543031G=, NC_000006.11:g.31543031G>A, NC_000006.12:g.31575254G=, NC_000006.12:g.31575254G>A, NG_007462.1:g.4682G=, NG_007462.1:g.4682G>A, NG_012010.1:g.8156G=, NG_012010.1:g.8156G>A, NM_000594.3:c.-488A>G, NM_000594.3:c.-488G>A, NT_113891.2:g.3052647A=, NT_113891.2:g.3052647A>G, NT_113891.3:g.3052541A=, NT_113891.3:g.3052541A>G, NT_167245.1:g.2828572G=, NT_167245.1:g.2828572G>A, NT_167245.2:g.2822987G=, NT_167245.2:g.2822987G>A, NT_167246.1:g.2885915G=, NT_167246.1:g.2885915G>A, NT_167246.2:g.2880295G=, NT_167246.2:g.2880295G>A, NT_167247.1:g.2922737G=, NT_167247.1:g.2922737G>A, NT_167247.2:g.2917152G=, NT_167247.2:g.2917152G>A, NT_167248.1:g.2836669G=, NT_167248.1:g.2836669G>A, NT_167248.2:g.2831073G=, NT_167248.2:g.2831073G>A, NT_167249.1:g.2873832G=, NT_167249.1:g.2873832G>A, NT_167249.2:g.2874534G=, NT_167249.2:g.2874534G>A, rs116610137, rs117441802, rs148958203, rs3091256, rs36205298, rs4134777, rs59729336
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1800630 NC_000006.11:g.31542476C=, NC_000006.11:g.31542476C>A, NC_000006.12:g.31574699C=, NC_000006.12:g.31574699C>A, NG_007462.1:g.4127C=, NG_007462.1:g.4127C>A, NG_012010.1:g.7601C=, NG_012010.1:g.7601C>A, NM_000594.3:c.-1043A>C, NM_000594.3:c.-1043C>A, NM_000595.3:c.*1006A>C, NM_000595.3:c.*1006C>A, NM_001159740.2:c.*1006A>C, NM_001159740.2:c.*1006C>A, NT_113891.2:g.3052092C=, NT_113891.2:g.3052092C>A, NT_113891.3:g.3051986C=, NT_113891.3:g.3051986C>A, NT_167245.1:g.2828017C=, NT_167245.1:g.2828017C>A, NT_167245.2:g.2822432C=, NT_167245.2:g.2822432C>A, NT_167246.1:g.2885360C=, NT_167246.1:g.2885360C>A, NT_167246.2:g.2879740C=, NT_167246.2:g.2879740C>A, NT_167247.1:g.2922182A=, NT_167247.1:g.2922182A>C, NT_167247.2:g.2916597A=, NT_167247.2:g.2916597A>C, NT_167248.1:g.2836114C=, NT_167248.1:g.2836114C>A, NT_167248.2:g.2830518C=, NT_167248.2:g.2830518C>A, NT_167249.1:g.2873277C=, NT_167249.1:g.2873277C>A, NT_167249.2:g.2873979C=, NT_167249.2:g.2873979C>A, XM_011514614.1:c.*1006A>C, XM_011514614.1:c.*1006C>A, XM_011514615.1:c.*1006A>C, XM_011514615.1:c.*1006C>A, XM_011514616.1:c.*1006A>C, XM_011514616.1:c.*1006C>A, XM_011514617.1:c.*1006A>C, XM_011514617.1:c.*1006C>A, XM_011514618.1:c.*1006A>C, XM_011514618.1:c.*1006C>A, XM_011547250.1:c.*1006A>C, XM_011547250.1:c.*1006C>A, XM_011547653.1:c.*1006A>C, XM_011547653.1:c.*1006C>A, XM_011547654.1:c.*1006A>C, XM_011547654.1:c.*1006C>A, XM_011547883.1:c.*1006A>C, XM_011547883.1:c.*1006C>A, XM_011547884.1:c.*1006A>C, XM_011547884.1:c.*1006C>A, XM_011547885.1:c.*1006A>C, XM_011547885.1:c.*1006C>A, XM_011547886.1:c.*1006A>C, XM_011547886.1:c.*1006C>A, XM_011547887.1:c.*1006A>C, XM_011547887.1:c.*1006C>A, XM_011548050.1:c.*1006A>C, XM_011548050.1:c.*1006C>A, XM_011548051.1:c.*1006A>C, XM_011548051.1:c.*1006C>A, XM_011548242.1:c.*1006A>C, XM_011548242.1:c.*1006C>A, XM_011548243.1:c.*1006A>C, XM_011548243.1:c.*1006C>A, XM_011548436.1:c.*1006A>C, XM_011548436.1:c.*1006C>A, XM_011548437.1:c.*1006A>C, XM_011548437.1:c.*1006C>A, XM_011548438.1:c.*1006A>C, XM_011548438.1:c.*1006C>A, XM_011548439.1:c.*1006A>C, XM_011548439.1:c.*1006C>A, XM_011548440.1:c.*1006A>C, XM_011548440.1:c.*1006C>A, XR_952245.1:n.-1977G>T, XR_952245.1:n.-1977T>G, rs112222934, rs114012139, rs117712855, rs181370386, rs36205300, rs3807037, rs4151110, rs4645836
C > A
SNP
No VIP available No Clinical Annotations available VA
rs1800750 NC_000006.11:g.31542963G=, NC_000006.11:g.31542963G>A, NC_000006.12:g.31575186G=, NC_000006.12:g.31575186G>A, NG_007462.1:g.4614G=, NG_007462.1:g.4614G>A, NG_012010.1:g.8088G=, NG_012010.1:g.8088G>A, NM_000594.3:c.-556A>G, NM_000594.3:c.-556G>A, NT_113891.2:g.3052579G=, NT_113891.2:g.3052579G>A, NT_113891.3:g.3052473G=, NT_113891.3:g.3052473G>A, NT_167245.1:g.2828504G=, NT_167245.1:g.2828504G>A, NT_167245.2:g.2822919G=, NT_167245.2:g.2822919G>A, NT_167246.1:g.2885847G=, NT_167246.1:g.2885847G>A, NT_167246.2:g.2880227G=, NT_167246.2:g.2880227G>A, NT_167247.1:g.2922669G=, NT_167247.1:g.2922669G>A, NT_167247.2:g.2917084G=, NT_167247.2:g.2917084G>A, NT_167248.1:g.2836601A=, NT_167248.1:g.2836601A>G, NT_167248.2:g.2831005A=, NT_167248.2:g.2831005A>G, NT_167249.1:g.2873764G=, NT_167249.1:g.2873764G>A, NT_167249.2:g.2874466G=, NT_167249.2:g.2874466G>A, rs147371058, rs3093659, rs36205297, rs4134776, rs4987026
G > A
SNP
No VIP available CA VA
rs1800795 NC_000007.13:g.22766645C>G, NC_000007.14:g.22727026C>G, NG_011640.1:g.4880C>G, NM_000600.4:c.-237C>G, NM_001318095.1:c.-274C>G, NR_131935.1:n.54-321G>C, XM_005249745.1:c.-237C>G, XM_005249745.3:c.-237C>G, XM_005249746.1:c.-274C>G, XM_011515390.1:c.-84-153C>G, XM_011515391.1:c.-274C>G, rs17777058, rs36215460, rs56588968, rs58302852
C > G
SNP
No VIP available CA VA
rs1801274 NC_000001.10:g.161479745A>G, NC_000001.11:g.161509955A>G, NG_012066.1:g.9541A>G, NM_001136219.1:c.500A>G, NM_021642.3:c.497A>G, NP_001129691.1:p.His167Arg, NP_067674.2:p.His166Arg, XM_005244960.1:c.500A>G, XM_011509287.1:c.500A>G, XM_011509288.1:c.497A>G, XM_011509289.1:c.500A>G, XM_011509290.1:c.500A>G, XM_011509291.1:c.500A>G, XP_005245017.1:p.His167Arg, XP_011507589.1:p.His167Arg, XP_011507590.1:p.His166Arg, XP_011507591.1:p.His167Arg, XP_011507592.1:p.His167Arg, XP_011507593.1:p.His167Arg, rs16830404, rs17851761, rs386545630, rs52796393, rs58440466
A > G
SNP
H167R
No VIP available No Clinical Annotations available VA
rs1980422 NC_000002.11:g.204610396C>T, NC_000002.12:g.203745673C>T, rs17246801, rs59734983, rs60654513
C > T
SNP
No VIP available No Clinical Annotations available VA
rs20575 NC_000008.10:g.23059324C>G, NC_000008.11:g.23201811C>G, NG_032107.1:g.28357G>C, NM_003844.3:c.626G>C, NP_003835.3:p.Arg209Thr, rs11550539, rs17398665, rs17759966, rs4871857, rs52835905, rs60716604
C > G
SNP
R209T
No VIP available No Clinical Annotations available VA
rs2104286 NC_000010.10:g.6099045T>C, NC_000010.11:g.6057082T>C, NG_007403.1:g.10228A>G, NM_000417.2:c.64+5006A>G, NM_001308242.1:c.64+5006A>G, NM_001308243.1:c.64+5006A>G, XM_005252446.1:c.64+5006A>G, XM_005252447.1:c.64+5006A>G, rs56454393, rs57657975
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2228145 NC_000001.10:g.154426970A>C, NC_000001.11:g.154454494A>C, NG_012087.1:g.54302A>C, NM_000565.3:c.1073A>C, NM_181359.2:c.1066+4514A>C, NP_000556.1:p.Asp358Ala, XM_005245138.1:c.1010A>C, XM_005245139.1:c.924+4514A>C, XM_005245140.1:c.931A>C, XM_006711298.1:c.1121A>C, XM_006711299.2:c.1114+4514A>C, XP_005245195.1:p.Asp337Ala, XP_005245197.1:p.Ile311Leu, XP_006711361.1:p.Asp374Ala, rs117579727, rs52837205, rs58037860, rs8192284
A > C
SNP
D358A
No VIP available No Clinical Annotations available VA
rs2476601 NC_000001.10:g.114377568A=, NC_000001.10:g.114377568A>G, NC_000001.11:g.113834946A=, NC_000001.11:g.113834946A>G, NG_011432.1:g.41808C=, NG_011432.1:g.41808C>T, NM_001193431.2:c.1858C=, NM_001193431.2:c.1858C>T, NM_001308297.1:c.1786C=, NM_001308297.1:c.1786C>T, NM_012411.5:c.1693C=, NM_012411.5:c.1693C>T, NM_015967.5:c.1858C>T, NM_015967.6:c.1858C=, NM_015967.6:c.1858C>T, NP_001180360.1:p.Arg620=, NP_001180360.1:p.Arg620Trp, NP_001295226.1:p.Arg596=, NP_001295226.1:p.Arg596Trp, NP_036543.4:p.Arg565=, NP_036543.4:p.Arg565Trp, NP_057051.3:p.Arg620=, NP_057051.3:p.Arg620Trp, NR_125965.1:n.414+19474A>G, NR_125965.1:n.414+19474G>A, XM_005270738.1:c.1786T=, XM_005270738.1:c.1786T>C, XM_005270738.2:c.1786T=, XM_005270738.2:c.1786T>C, XM_011541221.1:c.1780T=, XM_011541221.1:c.1780T>C, XM_011541222.1:c.1858T=, XM_011541222.1:c.1858T>C, XM_011541223.1:c.1858T=, XM_011541223.1:c.1858T>C, XM_011541224.1:c.1414T=, XM_011541224.1:c.1414T>C, XM_011541225.1:c.1786T=, XM_011541225.1:c.1786T>C, XP_005270795.1:p.Trp596=, XP_005270795.1:p.Trp596Arg, XP_011539523.1:p.Trp594=, XP_011539523.1:p.Trp594Arg, XP_011539524.1:p.Trp620=, XP_011539524.1:p.Trp620Arg, XP_011539525.1:p.Trp620=, XP_011539525.1:p.Trp620Arg, XP_011539526.1:p.Trp472=, XP_011539526.1:p.Trp472Arg, XP_011539527.1:p.Trp596=, XP_011539527.1:p.Trp596Arg, rs117063937, rs52834763, rs60104027
A > G
SNP
R620W
No VIP available No Clinical Annotations available VA
rs2736195 NC_000006.11:g.31542691A>G, NC_000006.12:g.31574914A>G, NG_007462.1:g.4342A>G, NG_012010.1:g.7816A>G, NM_000594.3:c.-828A>G, NT_113891.2:g.3052307A>G, NT_113891.3:g.3052201A>G, NT_167245.1:g.2828232A>G, NT_167245.2:g.2822647A>G, NT_167246.1:g.2885575A>G, NT_167246.2:g.2879955A>G, NT_167247.1:g.2922397A>G, NT_167247.2:g.2916812A>G, NT_167248.1:g.2836329A>G, NT_167248.2:g.2830733A>G, NT_167249.1:g.2873492A>G, NT_167249.2:g.2874194A>G
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2736340 NC_000008.10:g.11343973C>T, NC_000008.11:g.11486464C>T, rs58684812
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2812378 NC_000009.11:g.34710260G>A, NC_000009.12:g.34710263G>A, NM_002989.3:c.-197C>T, XM_011518004.1:c.-197C>T, XR_242544.1:n.124+7225G>A, rs16931795, rs386574189, rs57427236
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3087243 NC_000002.11:g.204738919G>A, NC_000002.12:g.203874196G>A, NG_011502.1:g.11411G>A, NM_001037631.2:c.*1421G>A, NM_005214.4:c.*1384G>A, XR_241294.1:n.2154G>A, rs56520936, rs57552006, rs57994510
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3093548 NC_000006.11:g.31542820C>T, NC_000006.12:g.31575043C>T, NG_007462.1:g.4471C>T, NG_012010.1:g.7945C>T, NM_000594.3:c.-699C>T, NT_113891.2:g.3052436C>T, NT_113891.3:g.3052330C>T, NT_167245.1:g.2828361C>T, NT_167245.2:g.2822776C>T, NT_167246.1:g.2885704C>T, NT_167246.2:g.2880084C>T, NT_167247.1:g.2922526C>T, NT_167247.2:g.2916941C>T, NT_167248.1:g.2836458C>T, NT_167248.2:g.2830862C>T, NT_167249.1:g.2873621C>T, NT_167249.2:g.2874323C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3218253 NC_000022.10:g.37544810G>A, NC_000022.11:g.37148770G>A, NM_000878.3:c.-34+1055C>T, XM_005261599.1:c.-33-4565C>T, rs57212492, rs58893919
G > A
SNP
No VIP available CA VA
rs361525 NC_000006.11:g.31543101G=, NC_000006.11:g.31543101G>A, NC_000006.12:g.31575324G=, NC_000006.12:g.31575324G>A, NG_007462.1:g.4752G=, NG_007462.1:g.4752G>A, NG_012010.1:g.8226G=, NG_012010.1:g.8226G>A, NM_000594.3:c.-418A>G, NM_000594.3:c.-418G>A, NT_113891.2:g.3052717G=, NT_113891.2:g.3052717G>A, NT_113891.3:g.3052611G=, NT_113891.3:g.3052611G>A, NT_167245.1:g.2828642A=, NT_167245.1:g.2828642A>G, NT_167245.2:g.2823057A=, NT_167245.2:g.2823057A>G, NT_167246.1:g.2885985G=, NT_167246.1:g.2885985G>A, NT_167246.2:g.2880365G=, NT_167246.2:g.2880365G>A, NT_167247.1:g.2922807G=, NT_167247.1:g.2922807G>A, NT_167247.2:g.2917222G=, NT_167247.2:g.2917222G>A, NT_167248.1:g.2836739A=, NT_167248.1:g.2836739A>G, NT_167248.2:g.2831143A=, NT_167248.2:g.2831143A>G, NT_167249.1:g.2873902G=, NT_167249.1:g.2873902G>A, NT_167249.2:g.2874604G=, NT_167249.2:g.2874604G>A, rs139679880, rs36205296, rs4134778
G > A
SNP
No VIP available CA VA
rs3761847 NC_000009.11:g.123690239G>A, NC_000009.12:g.120927961G>A, NG_023346.1:g.6213C>T, NM_001190945.1:c.-366+1153C>T, NM_005658.4:c.-1638C>T, rs57231462
G > A
SNP
No VIP available CA VA
rs3794271 NC_000012.11:g.20860093G>A, NC_000012.12:g.20707159G>A, NM_001145944.1:c.50+1078G>A, NM_001145945.1:c.404+1078G>A, NM_001145946.1:c.404+1078G>A, NM_017435.4:c.404+1078G>A, XM_005253394.1:c.404+1078G>A, XM_005253395.1:c.404+1078G>A, XM_005253396.1:c.50+1078G>A, XM_005253397.1:c.404+1078G>A, XM_005253397.2:c.404+1078G>A, XM_011520703.1:c.404+1078G>A, XM_011520704.1:c.404+1078G>A, XM_011520705.1:c.404+1078G>A, XM_011520706.1:c.50+1078G>A, XM_011520707.1:c.50+1078G>A, XM_011520708.1:c.50+1078G>A, XM_011520709.1:c.50+1078G>A, XM_011520710.1:c.404+1078G>A, XM_011520711.1:c.-150+1078G>A, XR_931308.1:n.759+1078G>A, rs57295874
G > A
SNP
No VIP available No Clinical Annotations available VA
rs394581 NC_000006.11:g.159482521C>T, NC_000006.12:g.159061489C>T, XM_011536288.1:c.621+2092G>A, XM_011536289.1:c.507+2092G>A, rs56472775, rs59212643, rs59433113, rs9456369
C > T
SNP
No VIP available CA VA
rs396991 NC_000001.10:g.161514542A>C, NC_000001.11:g.161544752A>C, NG_009066.1:g.10872T>G, NM_000569.6:c.634T>G, NM_001127592.1:c.631T>G, NM_001127593.1:c.526T>G, NM_001127595.1:c.526T>G, NM_001127596.1:c.523T>G, NP_000560.5:p.Phe212Val, NP_001121064.1:p.Phe211Val, NP_001121065.1:p.Phe176Val, NP_001121067.1:p.Phe176Val, NP_001121068.1:p.Phe175Val, XM_011509293.1:c.428-1553T>G, rs17857127, rs2229097, rs3171040, rs4151086, rs61228128
A > C
SNP
F212V
No VIP available No Clinical Annotations available VA
rs4248158 NC_000006.11:g.31542533C>T, NC_000006.12:g.31574756C>T, NG_007462.1:g.4184C>T, NG_012010.1:g.7658C>T, NM_000594.3:c.-986C>T, NM_000595.3:c.*1063C>T, NM_001159740.2:c.*1063C>T, NT_113891.2:g.3052149C>T, NT_113891.3:g.3052043C>T, NT_167245.1:g.2828074C>T, NT_167245.2:g.2822489C>T, NT_167246.1:g.2885417C>T, NT_167246.2:g.2879797C>T, NT_167247.1:g.2922239C>T, NT_167247.2:g.2916654C>T, NT_167248.1:g.2836171C>T, NT_167248.2:g.2830575C>T, NT_167249.1:g.2873334C>T, NT_167249.2:g.2874036C>T, XM_011514614.1:c.*1063C>T, XM_011514615.1:c.*1063C>T, XM_011514616.1:c.*1063C>T, XM_011514617.1:c.*1063C>T, XM_011514618.1:c.*1063C>T, XM_011547250.1:c.*1063C>T, XM_011547653.1:c.*1063C>T, XM_011547654.1:c.*1063C>T, XM_011547883.1:c.*1063C>T, XM_011547884.1:c.*1063C>T, XM_011547885.1:c.*1063C>T, XM_011547886.1:c.*1063C>T, XM_011547887.1:c.*1063C>T, XM_011548050.1:c.*1063C>T, XM_011548051.1:c.*1063C>T, XM_011548242.1:c.*1063C>T, XM_011548243.1:c.*1063C>T, XM_011548436.1:c.*1063C>T, XM_011548437.1:c.*1063C>T, XM_011548438.1:c.*1063C>T, XM_011548439.1:c.*1063C>T, XM_011548440.1:c.*1063C>T, rs115177064
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4248159 NC_000006.11:g.31542580C>A, NC_000006.12:g.31574803C>A, NG_007462.1:g.4231C>A, NG_012010.1:g.7705C>A, NM_000594.3:c.-939C>A, NM_000595.3:c.*1110C>A, NM_001159740.2:c.*1110C>A, NT_113891.2:g.3052196C>A, NT_113891.3:g.3052090C>A, NT_167245.1:g.2828121C>A, NT_167245.2:g.2822536C>A, NT_167246.1:g.2885464C>A, NT_167246.2:g.2879844C>A, NT_167247.1:g.2922286C>A, NT_167247.2:g.2916701C>A, NT_167248.1:g.2836218C>A, NT_167248.2:g.2830622C>A, NT_167249.1:g.2873381C>A, NT_167249.2:g.2874083C>A, XM_011514614.1:c.*1110C>A, XM_011514615.1:c.*1110C>A, XM_011514616.1:c.*1110C>A, XM_011514617.1:c.*1110C>A, XM_011514618.1:c.*1110C>A, XM_011547250.1:c.*1110C>A, XM_011547653.1:c.*1110C>A, XM_011547654.1:c.*1110C>A, XM_011547883.1:c.*1110C>A, XM_011547884.1:c.*1110C>A, XM_011547885.1:c.*1110C>A, XM_011547886.1:c.*1110C>A, XM_011547887.1:c.*1110C>A, XM_011548050.1:c.*1110C>A, XM_011548051.1:c.*1110C>A, XM_011548242.1:c.*1110C>A, XM_011548243.1:c.*1110C>A, XM_011548436.1:c.*1110C>A, XM_011548437.1:c.*1110C>A, XM_011548438.1:c.*1110C>A, XM_011548439.1:c.*1110C>A, XM_011548440.1:c.*1110C>A
C > A
SNP
No VIP available No Clinical Annotations available VA
rs4248160 NC_000006.11:g.31542693G>A, NC_000006.12:g.31574916G>A, NG_007462.1:g.4344G>A, NG_012010.1:g.7818G>A, NM_000594.3:c.-826G>A, NT_113891.2:g.3052309G>A, NT_113891.3:g.3052203G>A, NT_167245.1:g.2828234G>A, NT_167245.2:g.2822649G>A, NT_167246.1:g.2885577G>A, NT_167246.2:g.2879957G>A, NT_167247.1:g.2922399G>A, NT_167247.2:g.2916814G>A, NT_167248.1:g.2836331G>A, NT_167248.2:g.2830735G>A, NT_167249.1:g.2873494G>A, NT_167249.2:g.2874196G>A, rs140433197
G > A
SNP
No VIP available No Clinical Annotations available VA
rs4248163 NC_000006.11:g.31542828C>G, NC_000006.12:g.31575051C>G, NG_007462.1:g.4479C>G, NG_012010.1:g.7953C>G, NM_000594.3:c.-691C>G, NT_113891.2:g.3052444C>G, NT_113891.3:g.3052338C>G, NT_167245.1:g.2828369C>G, NT_167245.2:g.2822784C>G, NT_167246.1:g.2885712C>G, NT_167246.2:g.2880092C>G, NT_167247.1:g.2922534C>G, NT_167247.2:g.2916949C>G, NT_167248.1:g.2836466C>G, NT_167248.2:g.2830870C>G, NT_167249.1:g.2873629C>G, NT_167249.2:g.2874331C>G
C > G
SNP
No VIP available No Clinical Annotations available VA
rs4647198 NC_000006.11:g.31542335C>T, NC_000006.12:g.31574558C>T, NG_007462.1:g.3986C>T, NG_012010.1:g.7460C>T, NM_000594.3:c.-1184C>T, NM_000595.3:c.*865C>T, NM_001159740.2:c.*865C>T, NT_113891.2:g.3051951C>T, NT_113891.3:g.3051845C>T, NT_167245.1:g.2827876C>T, NT_167245.2:g.2822291C>T, NT_167246.1:g.2885219C>T, NT_167246.2:g.2879599C>T, NT_167247.1:g.2922041C>T, NT_167247.2:g.2916456C>T, NT_167248.1:g.2835973C>T, NT_167248.2:g.2830377C>T, NT_167249.1:g.2873136C>T, NT_167249.2:g.2873838C>T, XM_011514614.1:c.*865C>T, XM_011514615.1:c.*865C>T, XM_011514616.1:c.*865C>T, XM_011514617.1:c.*865C>T, XM_011514618.1:c.*865C>T, XM_011547250.1:c.*865C>T, XM_011547653.1:c.*865C>T, XM_011547654.1:c.*865C>T, XM_011547883.1:c.*865C>T, XM_011547884.1:c.*865C>T, XM_011547885.1:c.*865C>T, XM_011547886.1:c.*865C>T, XM_011547887.1:c.*865C>T, XM_011548050.1:c.*865C>T, XM_011548051.1:c.*865C>T, XM_011548242.1:c.*865C>T, XM_011548243.1:c.*865C>T, XM_011548436.1:c.*865C>T, XM_011548437.1:c.*865C>T, XM_011548438.1:c.*865C>T, XM_011548439.1:c.*865C>T, XM_011548440.1:c.*865C>T, XR_926695.1:n.-1860G>A, XR_952245.1:n.-1836G>A, XR_952708.1:n.-1895G>A, XR_952889.1:n.-1860G>A, XR_952970.1:n.-1895G>A, XR_953043.1:n.-1895G>A, XR_953113.1:n.-1860G>A, rs143866632
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4750316 NC_000010.10:g.6393260C>G, NC_000010.11:g.6351298C>G, XR_242715.1:n.1710C>G, XR_242715.2:n.3074C>G, rs56902976, rs61718694
C > G
SNP
No VIP available No Clinical Annotations available VA
rs4810485 NC_000020.10:g.44747947T>G, NC_000020.11:g.46119308T>G, NG_007279.1:g.6042T>G, NM_001250.4:c.51+914T>G, NM_001250.5:c.51+914T>G, NM_001302753.1:c.51+914T>G, NM_152854.3:c.51+914T>G, NR_126502.1:n.141+914T>G, XM_005260617.1:c.51+914T>G, XM_005260617.2:c.51+914T>G, XM_005260618.1:c.51+914T>G, XM_005260619.1:c.51+914T>G, XM_005260619.2:c.51+914T>G, XM_005260620.1:c.51+914T>G, XM_011529109.1:c.51+914T>G, XR_244157.1:n.130+914T>G, XR_244158.1:n.130+914T>G, XR_936660.1:n.145+914T>G, rs17841920, rs56530668, rs60204642
T > G
SNP
No VIP available No Clinical Annotations available VA
rs4987086 NC_000006.11:g.31542557G>A, NC_000006.12:g.31574780G>A, NG_007462.1:g.4208G>A, NG_012010.1:g.7682G>A, NM_000594.3:c.-962G>A, NM_000595.3:c.*1087G>A, NM_001159740.2:c.*1087G>A, NT_113891.2:g.3052173G>A, NT_113891.3:g.3052067G>A, NT_167245.1:g.2828098G>A, NT_167245.2:g.2822513G>A, NT_167246.1:g.2885441G>A, NT_167246.2:g.2879821G>A, NT_167247.1:g.2922263G>A, NT_167247.2:g.2916678G>A, NT_167248.1:g.2836195G>A, NT_167248.2:g.2830599G>A, NT_167249.1:g.2873358G>A, NT_167249.2:g.2874060G>A, XM_011514614.1:c.*1087G>A, XM_011514615.1:c.*1087G>A, XM_011514616.1:c.*1087G>A, XM_011514617.1:c.*1087G>A, XM_011514618.1:c.*1087G>A, XM_011547250.1:c.*1087G>A, XM_011547653.1:c.*1087G>A, XM_011547654.1:c.*1087G>A, XM_011547883.1:c.*1087G>A, XM_011547884.1:c.*1087G>A, XM_011547885.1:c.*1087G>A, XM_011547886.1:c.*1087G>A, XM_011547887.1:c.*1087G>A, XM_011548050.1:c.*1087G>A, XM_011548051.1:c.*1087G>A, XM_011548242.1:c.*1087G>A, XM_011548243.1:c.*1087G>A, XM_011548436.1:c.*1087G>A, XM_011548437.1:c.*1087G>A, XM_011548438.1:c.*1087G>A, XM_011548439.1:c.*1087G>A, XM_011548440.1:c.*1087G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs548234 NC_000006.11:g.106568034C>T, NC_000006.12:g.106120159C>T, rs13220305, rs56922927
C > T
SNP
No VIP available No Clinical Annotations available VA
rs55634887 NC_000006.11:g.31542883G>A, NC_000006.12:g.31575106G>A, NG_007462.1:g.4534G>A, NG_012010.1:g.8008G>A, NM_000594.3:c.-636G>A, NT_113891.2:g.3052499G>A, NT_113891.3:g.3052393G>A, NT_167245.1:g.2828424G>A, NT_167245.2:g.2822839G>A, NT_167246.1:g.2885767G>A, NT_167246.2:g.2880147G>A, NT_167247.1:g.2922589G>A, NT_167247.2:g.2917004G>A, NT_167248.1:g.2836521G>A, NT_167248.2:g.2830925G>A, NT_167249.1:g.2873684G>A, NT_167249.2:g.2874386G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs55994001 NC_000006.11:g.31542882C>T, NC_000006.12:g.31575105C>T, NG_007462.1:g.4533C>T, NG_012010.1:g.8007C>T, NM_000594.3:c.-637C>T, NT_113891.2:g.3052498C>T, NT_113891.3:g.3052392C>T, NT_167245.1:g.2828423C>T, NT_167245.2:g.2822838C>T, NT_167246.1:g.2885766C>T, NT_167246.2:g.2880146C>T, NT_167247.1:g.2922588C>T, NT_167247.2:g.2917003C>T, NT_167248.1:g.2836520C>T, NT_167248.2:g.2830924C>T, NT_167249.1:g.2873683C>T, NT_167249.2:g.2874385C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs6691117 NC_000001.10:g.207782931A>G, NC_000001.11:g.207609586A>G, NG_007481.1:g.118459A>G, NM_000573.3:c.4843A>G, NM_000651.4:c.6193A>G, NP_000564.2:p.Ile1615Val, NP_000642.3:p.Ile2065Val, XM_005273064.1:c.5809A>G, XM_006711166.2:c.6208A>G, XM_011509205.1:c.6208A>G, XP_005273121.1:p.Ile1937Val, XP_006711229.1:p.Ile2070Val, XP_011507507.1:p.Ile2070Val, rs59510794
A > G
SNP
I1615V
No VIP available No Clinical Annotations available VA
rs6822844 NC_000004.11:g.123509421G>T, NC_000004.12:g.122588266G>T, rs61272394
G > T
SNP
No VIP available No Clinical Annotations available VA
rs6920220 NC_000006.11:g.138006504G>A, NC_000006.12:g.137685367G>A, rs17264367, rs56495515, rs57269942, rs58273351
G > A
SNP
No VIP available No Clinical Annotations available VA
rs7527798 NC_000001.10:g.207872290T>C, NC_000001.11:g.207698945T>C, NM_175710.1:c.1143-244T>C, rs17186918, rs57821295
T > C
SNP
No VIP available No Clinical Annotations available VA
rs7574865 NC_000002.11:g.191964633T=, NC_000002.11:g.191964633T>G, NC_000002.12:g.191099907T=, NC_000002.12:g.191099907T>G, NG_012852.1:g.56293A=, NG_012852.1:g.56293A>C, NM_001243835.1:c.274-23582A=, NM_001243835.1:c.274-23582A>C, NM_003151.3:c.274-23582A=, NM_003151.3:c.274-23582A>C, XM_005246817.1:c.301-23582A=, XM_005246817.1:c.301-23582A>C, XM_005246817.3:c.301-23582A=, XM_005246817.3:c.301-23582A>C, XM_006712719.2:c.274-23582A=, XM_006712719.2:c.274-23582A>C, XM_011511704.1:c.301-23582A=, XM_011511704.1:c.301-23582A>C, XM_011511705.1:c.274-23582A=, XM_011511705.1:c.274-23582A>C, XM_011511706.1:c.301-23582A=, XM_011511706.1:c.301-23582A>C, rs52795984, rs57433953
T > G
SNP
No VIP available No Clinical Annotations available VA
rs763780 NC_000006.11:g.52101739T>C, NC_000006.12:g.52236941T>C, NG_031869.1:g.12560A>G, NM_052872.3:c.482A>G, NP_443104.1:p.His161Arg, XM_011514276.1:c.482A>G, XP_011512578.1:p.His161Arg, XR_926873.1:n.-173T>C, rs56499381, rs57501176
T > C
SNP
H161R
No VIP available CA VA
rs767455 NC_000012.11:g.6450945T>C, NC_000012.12:g.6341779T>C, NG_007506.1:g.5317A>G, NM_001065.3:c.36A>G, NP_001056.1:p.Pro12=, XM_005253758.1:c.-135A>G, XM_005253759.1:c.36A>G, XP_005253816.1:p.Pro12=, rs1139417, rs11546182, rs117779755, rs17404022, rs17847988, rs1800691, rs3179755, rs3203525
T > C
SNP
P12P
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Ig gamma-1 chain C region
Trade Names
  • Remicade
  • Remicade (Centocor Inc)
Brand Mixture Names

PharmGKB Accession Id

PA452639

Type(s):

Drug

Description

Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion

Source: Drug Bank

Pharmacogenetics

Pharmacodynamics

Infliximab is a chimeric monoclonal antibody with variable regions of a mouse anti-human TNF monoclonal antibody fused with human-mouse IgG1 kappa [Article:19729904]. It has affinity to the transmembrane tumor necrosis factor (TNF) -alpha and soluble trimers of TNF-alpha [Articles:19729904, 19837186]. Infliximab binds to TNF-alpha, which prevents the activation of TNF receptors (TNFRSF1A, TNFRSF1B). Infliximab also acts as a cytokine carrier because it prolongs the half-life of TNF-alpha with a final effect of inactivating TNF-alpha [Article:19729904].

Furthermore, infliximab downregulates production of inflammatory markers such as interleukin 1 (IL1A; IL1B), interleukin 6 (IL6), interferon gamma (IFNG); adhesion markers like soluble E-selectin (SELE) and intercellular adhesion molecule 1 (ICAM1); of metalloproteinases like matrix metallopeptidase 1 (MMP1), matrix metallopeptidase 3 (MMP3), and matrix metallopeptidase 9 (MMP9) [Article:19729904]. It decreases markers of coagulation and fibrinolysis, and circulating secretory phospholipase A2 [Article:19729904].

Cartilage oligomeric matrix protein (COMP), tumor necrosis factor (ligand) superfamily, member 11 (TNFSF11), and tumor necrosis factor receptor superfamily, member 11b (TNFRSF11B) levels were investigated as biomarkers for infliximab response [Article:19489652].

The differential changes in type I interferon (IFNA1) response gene activity appeared relevant to the clinical outcome of TNF blockade with infliximab in rheumatoid arthritis. This association is found for a set of IFNA1 response genes consisting of 2',5'-oligoadenylate synthetase 1, 40/46kDa (OAS1), lectin, galactoside-binding, soluble, 3 binding protein (LGALS3BP), myxovirus (influenza virus) resistance 2 (Mx2), 2'-5'-oligoadenylate synthetase 2, 69/71kDa (OAS2), and serpin peptidase inhibitor, clade G, member 1 (SERPING1) [Article:20096109].

The genes major histocompatibility complex, class II, DR beta 3 (HLA-DRB3), SH2 domain containing 1B (SH2D1B), and granulysin (GNLY) were part of a predictor model for infliximab treatment response [Article:19847310].

Osteoprotegerin (TNFRSF11B), stanniocalcin-1 (STC1), prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin 13 receptor alpha 2 (IL13RA2), and interleukin 11 (IL11) are identified as predictive panels of genes for (non-)response to infliximab in ulcerative colitis mucosal biopsies [Article:19700435].

Pharmacogenomics

Variants in the major histocompatibility complex, class II, DR beta 1 gene (HLA-DRB1), TNF gene, lymphotoxin alpha gene (LTA), tumor necrosis factor receptor superfamily, member 1B gene (TNFRSF1B), interleukin 1 beta gene (IL1B), and macrophage migration inhibitory factor gene (MIF) are studied in association with response to infliximab [Articles:19489652, 18309487]. Variants in the inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKBKB), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA), and toll-like receptor 4 gene (TLR4) are significantly associated with treatment response to anti-TNF agents (etanercept or infliximab) [Article:20448286]. Polymorphisms mapping to AF4/FMR2 family, member 3 (AFF3) and CD226 molecule (CD226) had a statistically significant association with the response to anti-TNF treatment (etanercept, infliximab or adalimumab) [Article:20444755]. Another study in patients receiving etanercept, infliximab, or adalimumab therapy observed statistically significant associations between response to anti-TNF therapy and a rheumatoid arthritis risk allele at the protein tyrosine phosphatase, receptor type, C (PTPRC) gene locus [Article:20309874]. A haplotype in the ADAM metallopeptidase domain 17 (ADAM17) region was associated with a clinical response to infliximab in patients with Crohn's disease [Article:17001292]. A genome-wide association study in 89 patients with rheumatoid arthritis, prospectively followed after beginning an anti-TNF therapy, found an association of response to anti-TNF therapy with polymorphisms in the following genes: v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB), paraoxonase (gene:PON1]), guanylate binding protein family, member 6 (GBP6), LAG1 homolog, ceramide synthase 6 (CERS6), Mps One Binder kinase activator-like 2B (MOB3B), and chromosome 9 open reading frame 72 (C9orf72) [Article:18615156]. Interleukin 23 receptor (IL23R) genotype was a predictor of early response to infliximab in patients with moderate-to-severe ulcerative colitis [Article:20197757]. The response to anti-TNFalpha treatment with infliximab in patients with rheumatoid arthritis is influenced by the Fc fragment of IgG, low affinity IIa, receptor (FCGR2A) and Fc fragment of IgG, low affinity IIIa, receptor (FCGR3A) genotypes [Articles:18930989, 19005160]. Other studies could not confirm an association with FCGR3A gene variation and the clinical response to infliximab [Articles:17108815, 17265480]. Variants in the ATP-binding cassette transporter genes ABCG2 and ABCB1 were not associated with response to infliximab therapy in Hungarian patients with inflammatory bowel diseases [Article:17505995].

Source: PharmGKB

Indication

To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. Neutralization of the biological activity of TNFa leads to an overall reduction in inflammation.

Source: Drug Bank

Pharmacology

Infliximab is a chimeric human-murine anti-human tumor necrosis factor (TNF) monoclonal antibody. It binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production

Source: Drug Bank

Half-Life

9.5 days

Source: Drug Bank

Chemical Properties

Chemical Formula

C6428H9912N1694O1987S46

Source: Drug Bank

Canonical SMILES

Not Available

Source: Drug Bank

Average Molecular Weight

144190.3000

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
LTB (source: Drug Bank)
TNF (source: Drug Bank)
TNFRSF1B (source: Drug Bank)

Drug Interactions

Interaction Description
trastuzumab - infliximab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. (source: Drug Bank)

Curated Information ?

Publications related to infliximab: 61

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy. Clinical and experimental immunology. 2015. Iwaszko M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis. Pharmacogenomics. 2015. Prieto-Pérez Rocío, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. The pharmacogenomics journal. 2015. Julià A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients. Archives of dermatological research. 2015. González-Lara Leire, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015. Viatte Sebastien, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. Pharmacogenetics and genomics. 2015. Canet Luz M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint, bone, spine : revue du rhumatisme. 2015. Swierkot Jerzy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients. Pharmacogenetics and genomics. 2015. Batalla Ana, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. BioMed research international. 2015. Canhão Helena, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between TNF-alpha (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-alpha blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis. Pharmacogenomics. 2015. Song Gwan Gyu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics. 2015. Montes Ariana, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics. 2015. Dávila-Fajardo Cristina Lucía, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Pharmacogenomics. 2014. Julià Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic?. Pharmacogenomics. 2014. Ponchel Frederique, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenetics and genomics. 2014. Montes Ariana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenetics and genomics. 2013. Dávila-Fajardo Cristina L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of TNF-alpha polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics. 2013. Tong Qiang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of Fcgamma receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA dermatology (Chicago, Ill.). 2013. Julià Marc, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. The pharmacogenomics journal. 2013. Bluett J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between tumor necrosis factor-alpha (TNF-alpha) promoter -308 G/A and response to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis. Modern rheumatology / the Japan Rheumatism Association. 2013. Zeng Zhen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013. Acosta-Colman Isabel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical reviews in allergy & immunology. 2013. Sivamani Raja K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis. European journal of clinical pharmacology. 2013. Lacruz-Guzmán Diana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS genetics. 2013. Cui Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics. 2013. Umićević Mirkov Maša, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. The pharmacogenomics journal. 2013. Prieto-Pérez R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint, bone, spine : revue du rhumatisme. 2012. Morales-Lara María José, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint, bone, spine : revue du rhumatisme. 2012. Daïen Claire Immediato, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
TNF-alpha -857 and -1031 polymorphisms predict good therapeutic response to TNF-alpha blockers in Chinese Han patients with ankylosing spondylitis. Pharmacogenomics. 2012. Tong Qiang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis. Inflammation. 2012. Pappas Dimitrios A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic and genomic predictors of anti-TNF response. Pharmacogenomics. 2011. Prajapati Rita, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis and rheumatism. 2010. Cui Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology (Oxford, England). 2010. Hassan Batool, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug discovery today. 2009. Tansey Malú G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis and rheumatism. 2009. Varani Katia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in care in pediatric Crohn disease. Journal of pediatric gastroenterology and nutrition. 2009. Colletti Richard B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. The pharmacogenomics journal. 2009. O'Rielly D D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2008. Tsukahara S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Human molecular genetics. 2008. Maxwell James R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis and rheumatism. 2008. Marotte Hubert, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Annals of the rheumatic diseases. 2008. Miceli-Richard C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Clinical pharmacology and therapeutics. 2008. Schinzari F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis and rheumatism. 2007. Guis Sandrine, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clinical and experimental rheumatology. 2008. Rooryck C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Archives of internal medicine. 2007. Sorrentino Dario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics. 2007. Coenen Marieke J H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007. Hyams Jeffrey, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug discovery today. 2007. Kooloos Wouter M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford, England). 2007. Seitz M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatology international. 2006. Lee Young Ho, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenetics and genomics. 2006. Willot Stéphanie, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scandinavian journal of rheumatology. 2006. Cuchacovich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Annals of the rheumatic diseases. 2005. Fonseca J E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford, England). 2005. Kang C P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Alimentary pharmacology & therapeutics. 2004. Louis E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis and rheumatism. 2003. Mugnier Benedicte, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Annals of the rheumatic diseases. 2003. Padyukov L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology. 2002. Vermeire Severine, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scandinavian journal of gastroenterology. 2002. Louis E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. The pharmacogenomics journal. 2002. Mascheretti S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001. Taylor K D, et al. PubMed

LinkOuts

GenBank:
J00228
Web Resource:
Wikipedia
UniProtKB:
P01857
DrugBank:
DB00065
Drugs Product Database (DPD):
2244016
Therapeutic Targets Database:
DAP000107

Clinical Trials

These are trials that mention infliximab and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.